Replumbing the lymphatic system with a pill: still a dream

microscope - pixabay

Currently no U.S. Food and Drug Administration–approved therapy can reestablish lymphatic circulation after a patient develops lymphedema. Up to 10 million people in the United States and more than 100 million around the world have lymphedema.

A phase II clinical trial at Stanford University School of Medicine tested whether the drug ubenimex, a leukemia treatment used in Japan, can spur the growth of new lymphatic vessels for patients with secondary leg lymphedema. It was the “first pharmaceutical company-sponsored trial for a medical treatment of lymphedema.”

Continue reading “Replumbing the lymphatic system with a pill: still a dream”

Metformin inhibits development of drug-resistant breast cancer

test tubes - pixabay - research

Breast, colon, lung and hematological cancers “have high rates” of acquired resistance to chemotherapy drugs, including aromatase inhibitors for breast cancer. This phenomena, multiple drug resistance (MDR), is a major impediment to long-term cancer treatment.

That makes this research, published online December 6, 2017, groundbreaking.

[We] present the important in vitro discovery that the development of MDR (in breast cancer cells) can be prevented, and that established MDR could be resensitized to therapy, by adjunct treatment with metformin (emphasis added).

Continue reading “Metformin inhibits development of drug-resistant breast cancer”